| 1 |
Heo KS, Chang E, Takei Y et al (2013) Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arterioscler Thromb Vasc Biol 33, 321-329
DOI
|
| 2 |
Bialik P and Wozniak K (2017) SUMO proteases as potential targets for cancer therapy. Postepy Hig Med Dosw (Online) 71, 997-1004
|
| 3 |
Mukhopadhyay D, Ayaydin F, Kolli N et al (2006) SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J Cell Biol 174, 939-949
DOI
|
| 4 |
Gong L, Ji WK, Hu XH et al (2014) Sumoylation differentially regulates Sp1 to control cell differentiation. Proc Natl Acad Sci U S A 111, 5574-5579
DOI
|
| 5 |
Wang CM, Brennan VC, Gutierrez NM, Wang X, Wang L and Yang WH (2013) SUMOylation of ATF3 alters its transcriptional activity on regulation of TP53 gene. J Cell Biochem 114, 589-598
DOI
|
| 6 |
Jacques C, Baris O, Prunier-Mirebeau D et al (2005) Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90, 2314-2320
DOI
|
| 7 |
Cheng J, Bawa T, Lee P, Gong L and Yeh ET (2006) Role of desumoylation in the development of prostate cancer. Neoplasia 8, 667-676
DOI
|
| 8 |
Chiu SY, Asai N, Costantini F and Hsu W (2008) SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol 6, e310
DOI
|
| 9 |
Abdel-Hafiz HA and Horwitz KB (2012) Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol 13, 10-18
DOI
|
| 10 |
Nait Achour T, Sentis S, Teyssier C et al (2014) Transcriptional repression of estrogen receptor alpha signaling by SENP2 in breast cancer cells. Mol Endocrinol 28, 183-196
DOI
|
| 11 |
Yuan WC, Lee YR, Huang SF et al (2011) A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 20, 214-228
DOI
|
| 12 |
Liou YC, Zhou XZ and Lu KP (2011) Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 36, 501-514
DOI
|
| 13 |
Lu KP and Zhou XZ (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8, 904-916
DOI
|
| 14 |
Min SH, Zhou XZ and Lu KP (2016) The role of Pin1 in the development and treatment of cancer. Arch Pharm Res 39, 1609-1620
DOI
|
| 15 |
Giacinti L, Claudio PP, Lopez M and Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11, 1-8
|
| 16 |
Girardini JE, Napoli M, Piazza S et al (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20, 79-91
DOI
|
| 17 |
Cheng J, Kang X, Zhang S and Yeh ET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131, 584-595
DOI
|
| 18 |
Chen CH, Chang CC, Lee TH et al (2013) SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. Cancer Res 73, 3951-3962
DOI
|
| 19 |
Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61, 7025-7029
|
| 20 |
Lee JY, Won HY, Park JH et al (2015) MEL-18 loss mediates estrogen receptor-alpha downregulation and hormone independence. J Clin Invest 125, 1801-1814
DOI
|
| 21 |
Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A and Milgrom E (2003) Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278, 12335-12343
DOI
|
| 22 |
Ishida A, Asano H, Hasegawa M et al (1993) Cloning and chromosome mapping of the human Mel-18 gene which encodes a DNA-binding protein with a new 'RING-finger' motif. Gene 129, 249-255
DOI
|
| 23 |
Sauvageau M and Sauvageau G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313
DOI
|
| 24 |
Won HY, Lee JY, Shin DH et al (2012) Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. FASEB J 26, 5002-5013
DOI
|
| 25 |
Lee JY, Park MK, Park JH et al (2014) Loss of the polycomb protein Mel-18 enhances the epithelialmesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 33, 1325-1335
DOI
|
| 26 |
Fu M, Wang C, Zhang X and Pestell R (2003) Nuclear receptor modifications and endocrine cell proliferation. J Steroid Biochem Mol Biol 85, 133-138
DOI
|
| 27 |
Sentis S, Le Romancer M, Bianchin C, Rostan MC and Corbo L (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19, 2671-2684
DOI
|
| 28 |
Liu XF and Bagchi MK (2004) Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 279, 15050-15058
DOI
|
| 29 |
Suzuki A, Sanda N, Miyawaki Y et al (2010) Downregulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem 285, 13444-13453
DOI
|
| 30 |
Blackmore JK, Karmakar S, Gu G et al (2014) The SMRT coregulator enhances growth of estrogen receptor-alphapositive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis. Endocrinology 155, 3251-3261
DOI
|
| 31 |
Melchior F (2000) SUMO--nonclassical ubiquitin. Annu Rev Cell Dev Biol 16, 591-626
DOI
|
| 32 |
Qiao Z, Wang W, Wang L et al (2011) Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorg Med Chem Lett 21, 6389-6392
DOI
|
| 33 |
Planas-Silva MD, Shang Y, Donaher JL, Brown M and Weinberg RA (2001) AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res 61, 3858-3862
|
| 34 |
Ishii S, Kurasawa Y, Wong J and Yu-Lee LY (2008) Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A 105, 4179-4184
DOI
|
| 35 |
Lim J, Song Y, Jang JH et al (2018) Aspirin-inspired acetyl-donating HDACs inhibitors. Arch Pharm Res 41, 967-976
DOI
|
| 36 |
Heo KS, Chang E, Le NT et al (2013) De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res 112, 911-923
DOI
|
| 37 |
Qin Y, Bao H, Pan Y et al (2014) SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma. Mol Med Rep 9, 877-881
DOI
|
| 38 |
Heo KS, Lee H, Nigro P et al (2011) PKCzeta mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol 193, 867-884
DOI
|
| 39 |
Heo KS, Berk BC and Abe J (2016) Disturbed flow-induced endothelial proatherogenic signaling via regulating posttranslational modifications and epigenetic events. Antioxid Redox Signal 25, 435-450
DOI
|
| 40 |
Deyrieux AF and Wilson VG (2017) Sumoylation in development and differentiation. Adv Exp Med Biol 963, 197-214
DOI
|
| 41 |
Kumar A, Ito A, Takemoto M, Yoshida M and Zhang KY (2014) Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening. J Chem Inf Model 54, 870-880
DOI
|
| 42 |
Madu IG, Namanja AT, Su Y, Wong S, Li YJ and Chen Y (2013) Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol 8, 1435-1441
DOI
|
| 43 |
Albrow VE, Ponder EL, Fasci D et al (2011) Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. Chem Biol 18, 722-732
DOI
|
| 44 |
Uno M, Koma Y, Ban HS and Nakamura H (2012) Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors. Bioorg Med Chem Lett 22, 5169-5173
DOI
|
| 45 |
Huang W, He T, Chai C et al (2012) Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One 7, e37693
DOI
|
| 46 |
Wu J, Lei H, Zhang J et al (2016) Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget 7, 58995-59005
DOI
|
| 47 |
Ma C, Wu B, Huang X et al (2014) SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9. Tumour Biol 35, 12729-12735
DOI
|
| 48 |
Shen HJ, Zhu HY, Yang C and Ji F (2012) SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev 13, 3583-3587
DOI
|
| 49 |
Tan M, Gong H, Wang J et al (2015) SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1. Sci Rep 5, 13996-14004
DOI
|
| 50 |
Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-10874
DOI
|
| 51 |
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502
DOI
|
| 52 |
Mander S, You DJ, Park S et al (2018) Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells. Arch Pharm Res 41, 229-242
DOI
|
| 53 |
Wang CM, Liu R, Wang L, Nascimento L, Brennan VC and Yang WH (2014) SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells. Int J Mol Sci 15, 10233-10251
DOI
|
| 54 |
Tan M, Zhang D, Zhang E et al (2017) SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-betaRI. Mol Carcinog 56, 2332-2341
DOI
|
| 55 |
Hu XY, Liu Z, Zhang KL et al (2017) SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells. Cancer Biomark 21, 195-201
DOI
|
| 56 |
Chang CC, Huang YS, Lin YM et al (2018) The role of sentrin-specific protease 2 substrate recognition in TGF-beta-induced tumorigenesis. Sci Rep 8, 9786-9798
DOI
|
| 57 |
Chen J, Kinyamu HK and Archer TK (2006) Changes in attitude, changes in latitude: nuclear receptors remodeling chromatin to regulate transcription. Mol Endocrinol 20, 1-13
DOI
|
| 58 |
Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15, 2302-2310
DOI
|
| 59 |
Pearce ST and Jordan VC (2004) The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50, 3-22
DOI
|
| 60 |
Chen GG, Zeng Q and Tse GM (2008) Estrogen and its receptors in cancer. Med Res Rev 28, 954-974
DOI
|
| 61 |
Lonard DM and O'Malley BW (2007) Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 27, 691-700
DOI
|
| 62 |
Smith CL, Migliaccio I, Chaubal V et al (2012) Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat 136, 253-265
DOI
|
| 63 |
Peterson TJ, Karmakar S, Pace MC, Gao T and Smith CL (2007) The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 27, 5933-5948
DOI
|
| 64 |
Privalsky ML (2004) The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66, 315-360
DOI
|
| 65 |
Green AR, Burney C, Granger CJ et al (2008) The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 110, 427-437
DOI
|
webmaster
